Foghorn Therapeutics Inc.
FHTX
$5.41
-$0.12-2.17%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 7.56M | 5.95M | 2.86M | 7.81M | 6.89M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 7.56M | 5.95M | 2.86M | 7.81M | 6.89M |
| Cost of Revenue | 21.79M | 21.63M | 20.51M | 24.69M | 23.80M |
| Gross Profit | -14.24M | -15.67M | -17.65M | -16.88M | -16.91M |
| SG&A Expenses | 6.86M | 7.24M | 6.35M | 6.97M | 7.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.65M | 28.87M | 26.86M | 31.66M | 31.12M |
| Operating Income | -21.10M | -22.91M | -24.01M | -23.85M | -24.23M |
| Income Before Tax | -17.94M | -18.83M | -19.50M | -19.12M | -22.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -17.94M | -18.83M | -19.50M | -19.12M | -22.98M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -17.94M | -18.83M | -19.50M | -19.12M | -22.98M |
| EBIT | -21.10M | -22.91M | -24.01M | -23.85M | -24.23M |
| EBITDA | -20.25M | -22.09M | -23.24M | -23.12M | -23.44M |
| EPS Basic | -0.28 | -0.30 | -0.31 | -0.31 | -0.45 |
| Normalized Basic EPS | -0.18 | -0.19 | -0.19 | -0.19 | -0.25 |
| EPS Diluted | -0.28 | -0.30 | -0.31 | -0.31 | -0.45 |
| Normalized Diluted EPS | -0.18 | -0.19 | -0.19 | -0.19 | -0.25 |
| Average Basic Shares Outstanding | 62.98M | 62.85M | 62.87M | 62.60M | 51.58M |
| Average Diluted Shares Outstanding | 62.98M | 62.85M | 62.87M | 62.60M | 51.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |